Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of the bone morphogenetic protein pathway suppresses tumor growth through downregulation of epidermal growth factor receptor in MEK/ERK-dependent colorectal cancer.
Shimizu S, Kondo J, Onuma K, Coppo R, Ota K, Kamada M, Harada Y, Tanaka Y, Nakazawa MA, Tamada Y, Okuno Y, Kawada K, Obama K, Coffey RJ, Fujiwara Y, Inoue M. Shimizu S, et al. Among authors: harada y. Cancer Sci. 2023 Sep;114(9):3636-3648. doi: 10.1111/cas.15882. Epub 2023 Jun 25. Cancer Sci. 2023. PMID: 37357017 Free PMC article.
A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, Hirakawa A, Tateishi U, Miyake S, Ikeda S. Takahashi K, et al. Among authors: harada y. Medicine (Baltimore). 2020 Aug 7;99(32):e21457. doi: 10.1097/MD.0000000000021457. Medicine (Baltimore). 2020. PMID: 32769873 Free PMC article.
Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.
Tachibana T, Tanaka M, Noguchi Y, Najima Y, Sadato D, Harada Y, Tamai Y, Doki N, Nakajima H. Tachibana T, et al. Among authors: harada y. Hematology. 2024 Dec;29(1):2360843. doi: 10.1080/16078454.2024.2360843. Epub 2024 Jun 3. Hematology. 2024. PMID: 38828928
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K, Shirane S, Shingai N, Toya T, Shimizu H, Haraguchi K, Kobayashi T, Harada H, Okuyama Y, Harada Y, Doki N. Kaito S, et al. Among authors: harada y. Bone Marrow Transplant. 2024 May 23. doi: 10.1038/s41409-024-02311-5. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38783125
Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.
Takazono T, Namie H, Nagayoshi Y, Imamura Y, Ito Y, Sumiyoshi M, Ashizawa N, Yoshida M, Takeda K, Iwanaga N, Ide S, Harada Y, Hosogaya N, Takemoto S, Fukuda Y, Yamamoto K, Miyazaki T, Sakamoto N, Obase Y, Sawai T, Higashiyama Y, Hashiguchi K, Funakoshi S, Suyama N, Tanaka H, Yanagihara K, Izumikawa K, Mukae H. Takazono T, et al. Among authors: harada y. Respirology. 2024 May 20. doi: 10.1111/resp.14752. Online ahead of print. Respirology. 2024. PMID: 38769707
2,773 results